Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | UBE2N | P61088 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962907 | 0.91 | SCN4A (0.49) | KMT2AL3MBTL1KDM4ESCN9A | |
| SCHEMBL15090773 | 0.85 | SCN9A (0.46) | KMT2AL3MBTL1KDM4ESCN9AALDH1A1 | |
| SCHEMBL14150735 | 0.84 | KMT2A (0.64) | KMT2AL3MBTL1KDM4EUBE2NMAPT | |
| SCHEMBL30078274 | 0.83 | ALDH1A1 (0.50) | KMT2AL3MBTL1KDM4ESCN9ACA12 | |
| SCHEMBL19778587 | 0.83 | KMT2A (0.54) | KMT2AL3MBTL1KDM4EUBE2NMAPT | |
| SCHEMBL725497 | 0.82 | CYP2C9 (0.53) | KMT2AL3MBTL1KDM4ESCN9AMAPT | |
| SCHEMBL14247709 | 0.81 | SCN9A (0.42) | L3MBTL1KDM4ESCN9AMAPTALDH1A1 | |
| SCHEMBL6531865 | 0.80 | SCN9A (0.51) | KMT2AL3MBTL1KDM4ESCN9ACA12 | |
| SCHEMBL28088814 | 0.79 | ALDH1A1 (0.51) | KMT2AL3MBTL1SCN9ACA12CA1 | |
| SCHEMBL28291686 | 0.79 | KMT2A (0.50) | KMT2AL3MBTL1KDM4EUBE2NMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526098-B1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-07-11 | — | — | EP | claimed |
| EP-2609091-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | Lead Discovery Center GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| US-8470820-B2 | Nitrogen-containing heteroaryl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-06-25 | — | — | US | claimed |
| WO-2012028332-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2012-03-08 | — | — | WO | claimed |
| WO-2023283369-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-4028395-A1 | SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-07-20 | — | — | EP | disclosed |
| EP-2526098-B1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-07-11 | — | — | EP | disclosed |
| EP-2609091-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | Lead Discovery Center GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-8470820-B2 | Nitrogen-containing heteroaryl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-06-25 | — | — | US | disclosed |
| WO-2012028332-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| US-20090143455-A1 | Pyrazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-06-04 | — | — | US | disclosed |
| CN-1050382-A | Pyrazole derivatives and preparation method thereof and medicinal compositions | FUJISAWA PHARMACEUTICAL CO (JP) | 1991-04-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143455-A1 | Pyrazoles Useful in the Treatment of Inflammation | ALOX15, ALOX12, ALOX15B | KMT2A 4432/4885L3MBTL1 2718/4885KDM4E 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.